(a).

in which $X^{\backslash}_{1},\dots X_{n}$ represents a sequence 3-4 of amino acids, wherein the amino acid sequence $X_1 \dots X_n$ is selected from the group consisting of the amino acid sequences VGG, VLSG, ATG, VSG, DSG, VVSG, ALAG, SEU IDAU

APSG and VGR, and

a nucleotide sequence which codes for an amino acid sequence with an (b) equivalent recognition specificity, as achieved with a T cell receptor comprising a CDR3 region with the amino acid sequence of SEQ ID NO. 23, for the peptide component of the T cell receptor ligands;

wherein the CDR3 region is at least 90% identical with the amino sequence of

SUS IZ (Twice Amended) Nucleic acid as claimed in claim 2 wherein the amino acid sequence X_1 . X_n is selected from the group consisting of amino acid sequences VGG, WLSG and ATG.

6. (Twice Amended) An isolated cell wherein it expresses a nucleic acid as claimed in claim 2 or 4.

Sub 155 (Twice Amended) Pharmaceutical composition which contains as an 26. active component a nucleic acid as claimed in one of the claims 2 or 4, or a cell as claimed in claim 6 or 7 optionally together with other active components as well as common pharmaceutical auxiliarly agents, additives or carrier substances.